Bio Green Med Solution Inc. has completed the sale of certain assets, including all patent rights related to Plogosertib, a PLK1 inhibitor for advanced cancers and hematological malignancies, to Tethra Biosciences Inc. The transaction was finalized for $300,000, with the potential for an additional $170,000 milestone payment.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bio Green Med Solution Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-017223), on October 07, 2025, and is solely responsible for the information contained therein.